IMPORTANCE YARS2 mutations have been associated with a clinical triad of myopathy, lactic acidosis, and sideroblastic anemia in predominantly Middle Eastern populations. However, the identification of new patients expands the clinical and molecular spectrum of mitochondrial disorders.
C hildhood-onset mitochondrial disease is among the most common inherited neurologic disorders, with an estimated minimum point prevalence of 5 (95% CI, 4.0-6.2) in 100 000 population. 1 Moreover, recent studies have estimated the prevalence of mitochondrial disease in affected adults at 9.6 per 100 000 caused by mutations in mitochondrial DNA (mtDNA) and 2.9 per 100 000, caused by nuclear mutations. 2 Hence, overall disease burden is potentially extensive. Patients exhibit marked phenotypic and genotypic heterogeneity, with mitochondrial respiratory chain complex deficiency a hallmark feature in tissues.
The amino-acyl transfer RNA (tRNA) synthetases are a group of enzymes critical for protein synthesis that are required for the recognition and conjugation of specific amino acids. Two sets of synthetases are encoded by separate genes in human cells, distinguished by cytoplasmic (referred to as ARS) or mitochondrial (referred to as ARS2) localization. ARS2 mutations have emerged as an important cause of mitochondrial translation disorders that first appeared to manifest in tissue and cell-type specific phenotypes, including central nervous system involvement (CARS2, DARS2, EARS2, FARS2, GARS, IARS2, MARS2, NARS2, PARS2, RARS2, TARS2, and VARS2); myopathy, lactic acidosis, and sideroblastic anemia (MLASA) (YARS2); hypertrophic cardiomyopathy (AARS2); sensorineural hearing loss and ovarian dysgenesis (Perrault syndrome) (LARS2 and HARS2); and hyperuricemia, pulmonary hypertension, renal failure, and alkalosis (SARS2). [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] Mutations of YARS2 encoding mitochondrial tyrosyltRNA synthetase have been described predominantly in patients with infantile-to childhood-onset autosomal recessive MLASA syndrome with mitochondrial respiratory chain complex deficiencies. 4, [19] [20] [21] [22] [23] The MLASA syndrome was first described in patients with PUS1 mutations, 24 with YARS2 mutations later identified in patients with a clinically similar phenotype, 4 and most recently in 2 patients with a novel de novo heteroplasmic m.8969G>A (MT-ATP6) and recessive LARS2 variants. 25, 26 Although rare, sideroblastic anemia is a prominent feature in Pearson syndrome caused by single, largescale mtDNA deletions.
27,28
We present 6 adult patients with YARS2 variants, including 4 previously unreported patients of Scottish descent, and demonstrate a new YARS2 founder effect within this population, with immunoblotting and yeast modeling of novel missense variants to confirm pathogenicity. Together with previous cases from the literature, we review the spectrum of clinical features and progression of YARS2-associated mitochondrial disease to fully delineate the clinical phenotype and genotype correlates.
Methods

Patients
Six patients (1.1, 1.2, 2, 3, 4.1, and 4.2) were referred to a national diagnostic and clinical center in Newcastle upon Tyne, England. Patients 1.1 and 1.2 were initially described in 1974. 29 Total genomic DNA was extracted and muscle biopsies were taken with written informed consent by standard procedures. We performed a literature review to identify all previously published cases with YARS2 variants. 4, [19] [20] [21] [22] [23] This study was approved and performed under the ethical guidelines issued by North East-Newcastle and North Tyneside institutional review board and complied with the Declaration of Helsinki. 30 Patients provided written informed consent.
Muscle Histochemistry and Respiratory Chain Enzyme Analysis
Muscle biopsy samples were subjected to cytochrome-c oxidase (COX), succinate dehydrogenase (SDH), and sequential COX-SDH histochemical reaction. 31 Measurement of mitochondrial respiratory chain complex activities in skeletal muscle homogenates was performed as previously described.
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Mitochondrial DNA Studies
Whole mitochondrial genome sequencing was performed using skeletal muscle homogenate to exclude pathogenic point mutations. Mitochondrial DNA rearrangements and mtDNA depletion were excluded using established, diagnostic, long-range polymerase chain reaction, and quantitative real-time polymerase chain reaction assays, respectively. Haplogroups were classified using HaploGrep.
33
Identification of Pathogenic YARS2 Variants YARS2-targeted gene screening or variants identified by whole exome sequencing were confirmed by Sanger sequencing using custom-designed primers for all 5 exons and intronic regions of YARS2 (GenBank NM_001040436.2). Patient 4.1 was the first to have the diagnosis identified by whole exome sequencing, 34 followed by patients 2 and 3 with a separate exome filtering pipeline. 35 Targeted YARS2 gene screening was performed on patient 1.1.
Identification of Founder YARS2 Mutation
Short tandem repeat tracts flanking the YARS2 gene were identified using the Repeat Masker track of the University of California, Santa Cruz (UCSC) genome browser (http://genome.ucsc.edu), 36 and primers were designed using Primer3 (http://primer3.ut.ee/). 37 Patient DNA was amplified across the various short tandem repeat loci by using polymerase chain reaction. Use of a fluorescently tagged forward primer facilitated electrophoresis on an ABI3130xl genetic analyzer. Sizing and genotyping were performed (Peak Scanner, version 1.0; Applied Biosystems) with standard analysis parameters; ROX500 (Applied Biosystems) was used as a size standard.
Immunoblotting
Total protein aliquots from fibroblasts and myoblasts of patient 3 plus 2 controls for each cell line were separated through the use of sodium dodecyl sulfate polyacrylamide gel electrophoresis. Membranes were probed with antibodies specific to YARS2 (AP7838; Abgent), SDHA (ab14715; Abcam), ATP5B (ab14730; Abcam), UQCRC2 (ab14745; Abcam), MT-COI (ab14705; Abcam), MT-COII (ab110258; Abcam), and NDUFB8 (ab110242; Abcam). β-Actin (A5316; Sigma-Aldrich) and VDAC1/ Porin (ab14734; Abcam) were used as loading controls.
Yeast Modeling
Yeast strains were generated and cultured as described in the eMethods in the Supplement. Human YARS2 is highly conserved in phylogenesis including yeast. The human residue Leu392 is conserved from human to yeast (Leu411) (eFigure, CintheSupplement), and the mutant allele corresponding to the novel missense variant identified in the patient of our cohort was generated (msy
L411S
). The human residue Cys369 is, however, not conserved in yeast (Leu391) (eFigure, C in the Supplement). For this nonconserved residue, we mutagenized the yeast sequence to replace the amino acid leucine of the wild-type Msy1 with the amino acid cysteine of the wildtype human YARS2, thus creating the so-called "humanized" version (hL391C). If the humanized wild-type variant is able to complement the oxidative growth defect of the msy1Δ strain, it is possible to evaluate the effects of the novel missense variant identified in our cohort (Cys369Tyr) by creating the corresponding yeast mutant allele msy1
L391Y
. Oligonucleotides are provided in eTable 1 in the Supplement. Oxidative growth and mitochondrial respiration were measured as described previously. 19 The full methodology is provided in the eMethods in the Supplement.
Statistical Analysis
A paired, 2-tailed t test was performed to examine the yeast mitochondrial respiratory rate, and the level of statistical significance was set at P ≤ .05. Microsoft Excel 2016 (Microsoft Corp) was used for statistical analysis.
Results
Clinical Features
We present 6 patients referred to our national diagnostic center with confirmed YARS2 variants ( Figure 1 ).
Muscle Histochemistry and Muscle Respiratory Chain Enzyme Activity Analysis
Skeletal muscle biopsy specimens were available for 8 of the 17 patients (47%) (eTable 2 in the Supplement). Global COX deficiency was evident in 4 patients ( Figure 2) ; ragged red fibers were observed in 2 patients. Patient 7 had a marked increase in SDH activity, but patient 13.1 exhibited only a minimal increase. Other abnormalities included lipid vacuoles (patient 9) and a few myopathic hypoatrophic fibers (patient 13.1).
Muscle respiratory chain enzyme activity was measured in 10 patients. Combined complex I, III, and IV deficiencies were found in 6 patients; complex I and IV deficiencies were found in the remaining 4 individuals.
Identification of Pathogenic YARS2 Variants
In our cohort, we identified 3 novel pathogenic YARS2 variants (c.1106G>A p.Cys369Tyr, c.1147_1164dup p.Val383_Glu388dup, and c.1175T>C p.Leu392Ser) and a previously reported variant (c.137G>A p.Gly46Asp). 22 The p.Cys369Tyr substitution is absent from external databases (ExAC, ESP6500, and 1000 Genomes Project) and affects a highly conserved residue; the impact of the missense substitution is predicted to be deleterious according to SIFT and MutationTaster; PolyPhen2 and AlignGVGD are more conservative with their predictions. Because of the proximity of the c.1106G>A nucleotide to the intron-exon boundary, the c.1106G>A substitution may cause aberrant messenger RNA splicing and, in addition, it is predicted to abolish a SC35 exonic splicing enhancer according to the in silico splicing prediction tool ESEfinder. The p.Val383_Glu388dup variant was found in 2 of 121 360 (1.648 × 10
) alleles in ExAC from 2 nonFinnish European individuals. The p.Leu392Ser missense change was found in 1 of 121 354 alleles in ExAC in a single non-Finnish European individual and is predicted to be deleterious according to SIFT and MutationTaster; however, PolyPhen2 and AlignGVGD predict a milder effect of the p.Leu392Ser substitution (ExAC, ESP6500, and 1000 Genomes Project frequency data, accessed June 22, 2016). To date, there is a total of 9 pathogenic variants described in the YARS2 gene ( Figure 3A ). All variants lead to missense changes except for a 6-amino acid duplication within the S4-like domain and a nonsense variant that is likely to lead to degradation of messenger RNA by nonsense-mediated decay. 21 All patients harbored homozygous missense changes except for patients 3 and 12, who had compound heterozygous changes. The Lebanese founder p.Phe52Leu variant was the most frequent pathogenic YARS2 variant, occurring in 5 patients.
We identified 2 patients (1.1 and 2) from 2 apparently unrelated families of Scottish ancestry with a homozygous p.Leu392Ser variant in the S4-like domain. Patient 2 was born to consanguineous parents. Formal genetic testing of patient 1.2, a clinically affected sibling of patient 1.1, was not feasible; however, their clinically unaffected sister was tested and did not harbor the familial variant. We also identified a third patient of Scottish ancestry (patient 3) with unreported (p.Cys369Tyr and p.Val383_Glu388dup) compound heterozygous variants in which familial segregation studies confirmed recessive inheritance.
Identification of Founder YARS2 Mutation
Microsatellite genotyping of dinucleotide repeat regions flanking the YARS2 gene supported a common founder across a region of at least 183 kb shared between unrelated patients 1.1 and 2 with a T-1-2-3 haplotype consisting of the YARS2 p.Leu392Ser mutation plus markers ms3, ms2, and ms1. Analysis of DNA from the unaffected sister of patient 1.1, whose genetic status was homozygous wild type at the p.Leu392Ser locus, was as anticipated: consistent with inheritance of the normal paternal and maternal alleles ( Figure 3B ).
Assessment of Mitochondrial DNA
Pathogenic or likely pathogenic mtDNA point mutations, rearrangements, and depletion were excluded. All of the patients from our center belonged to different haplogroups (Table 1 and eTable 3 in the Supplement).
Immunoblotting Analysis
Immunoblotting of total protein aliquots from cultured skin fibroblasts and myoblasts of patient 3 showed no change in immunoreactive YARS2 levels (eFigure, A and B in the Supplement). A minimal reduction of MT-COI was observed in both fibroblasts and myoblasts, whereas a marked decrease in NDUFB8 was observed only in myoblasts.
Yeast Modeling
Oxidative growth of the strains expressing msy L411S and the humanized version msy1 hL391C was similar to the wild type at 28°C
and 36°C, whereas growth of the strain expressing msy1 L391Y was reduced, particularly at 36°C (eFigure, D in the Supplement). Oxygen consumption of cells grown at 28°C showed a reduction for both of the mutants: mutant msy1 L391Y showed a 27% reduction of the respiratory rate with respect to its ; these features are conspicuously absent in YARS2-related mitochondrial disease. In contrast, hypertrophic cardiomyopathy is a clinical feature that has been identified independently in 8 family pedigrees with YARS2 mutations (eTable 2 in the Supplement) compared with only a single case of PUS1 mutations. 41 Although there are emerging phenotypic differences observed between these 2 genetic mutations, caution should be applied on drawing firm conclusions given the relatively small number of patients in these 2 cohorts to date. We have observed full resolution of sideroblastic anemia in 2 of the patients from our center and other previously reported patients with YARS2 mutations. The exact mechanism of such a phenomenon in YARS2 mutations is unknown given the other salient clinical features, including myopathy and cardiomyopathy, frequently progress over time. In another form of mitochondrial disease, the spontaneous resolution of sideroblastic anemia in Pearson syndrome has been speculated to be the result of negative selection of mutant mtDNA in the bone marrow. 44 This is a feature that warrants further work but is beyond the scope of this article. Severe respiratory muscle weakness leading to ventilation failure, especially in adult patients, is a rare clinical feature in mitochondrial disease 45-47 compared with other genetic muscle diseases. 48 Analysis of all cases would suggest this is a key, terminal feature combined with hypertrophic cardiomyopathy and/or refractory transfusion-dependent sideroblastic anemia in the natural progression of YARS2-associated mitochondrial disease. These findings highlight the importance of regular surveillance of respiratory and cardiac function. Furthermore, early instigation of supportive treatment, such as noninvasive ventilation and pharmacologic cardiac remodeling agents, 49 may slow disease progression.
The muscle biopsy findings of severe, global COX deficiency in muscle fibers were consistent with a diagnosis of mitochondrial myopathy and prompted further investigation. Immunoblotting of fibroblasts and myoblasts from patient 3 demonstrated no change in YARS2 protein levels; immunoblotting of fibroblasts, myoblasts, or MyoD-forced myotubes from 2 patients (8.2 and 12) also showed no decrease. 4, 21 In contrast, YARS2 levels were undetectable in myoblasts and myotubes from patient 7. 22 This may reflect the tissue-specific nature of YARS2 and other aminoacyl tRNA synthetase mutations and variation in the threshold for expression between different individuals and tissues. One factor contributing to this variation may be the rate of protein turnover in an individual tissue. Our data illustrating only a minor decrease in MT-COI and MT-COII levels in patient fibroblasts and myoblasts despite marked COX deficiency in muscle lend support to this argument. Yeast modeling to confirm pathogenicity of the reported p.Asp311Glu variant, corresponding to msy D333E , had been performed previously demonstrating an OXPHOS defect by failure to grow on media containing ethanol. 19 We replicated this for our unreported missense changes, p.Leu392Ser and p.Cys369Tyr, corresponding to msy L411S and msy L391Y . Both 
Limitations
Predicting the severity and speed of disease progression is challenging given the genetic heterogeneity of this disorder. Homozygous mutations in p.Gly46Asp appear to manifest later in childhood compared with the p.Phe52Leu and p.Ser435Gly variants. We now describe 3 unrelated patients of Scottish ancestry with homozygous p.Leu392Ser mutations who presented with slower disease progression and survival into late adulthood. It has been hypothesized that mtDNA haplotype background may influence phenotypic expression.
21,50,51
Within our patient cohort, haplotype H was associated with slower disease progression and a less severe phenotype as previously observed. 21 Patient 2, who presented with the mildest phenotype of all YARS2 patients, belonged to haplogroup G (Table 1 and eTable 3 in the Supplement), which, to our knowledge, has not been previously reported. However, as with previous phylogenetic analysis and characterization of mtDNA haplogroups in patients with YARS2, 21 there are likely additional, indeterminate genetic factors that modify phenotypic expression of disease. The advent of next-generation sequencing has permitted the identification of patients with YARS2 mutations who do not manifest with the full MLASA syndromic features, thus further expanding the phenotypic and genotypic heterogeneity of these mitochondrial disorders. This is exemplified by the identification of a 73-year-old patient with characteristic global COX deficiency in muscle who harbored recessive YARS2 variants and manifests remarkably indolent, progressive, mitochondrial myopathy.
Conclusions
YARS2-related mitochondrial disease is phenotypically heterogeneous and has a variable prognosis ranging from infantileonset-and often fatal-MLASA syndrome to later adolescentonset, slowly progressive myopathy. Progressive respiratory muscle weakness and cardiomyopathy are the major causes of death in these patients. We suggest that YARS2-associated mitochondrial disease may be an underdiagnosed clinical entity, particularly in populations outside the Middle East and in adult patients who do not exhibit the full clinical spectrum of MLASA, as we demonstrate a new Scottish YARS2 founder effect within our patient population. -1 leu2-3, 112 ura3-1 trp1-1 his3-11, 15 can1-100 . All experiments except transformation were performed in synthetic complete media (0.69% YNB without amino acids powder, ForMedium) supplemented with 1g/l dropout mix without amino acids or bases necessary to keep plasmids (i.e. uracil for pFL38 and tryptophan for the pFL39). 1 Media were supplemented with various carbon sources at 2% (w/v) (Carlo Erba Reagents), in liquid phase or after solidification with 20g/l agar (ForMedium). Transformation was performed as previously described after growth in YPAD medium (1% Yeast extract, 2% Peptone, 40 mg/l adenine base and 2% glucose).
2
MSY1 was previously cloned under its natural promoter by PCR-amplification with oligonucleotides MSY1cFw and MSY1cRv (Supplementary eTable 1) 3 and the HindIII-KpnIdigested MSY1 fragment was inserted into the pFL38. 4 The pFL38-MSY1 plasmid was introduced into the W303-1B strain through the Li-Ac method 2 and disruption of the genomic MSY1 gene was performed in this strain, since the deletion leads to mitochondrial DNA loss. 5 Disruption was performed through one-step gene disruption by PCR-amplification of KanMX4 cassette 6 from the BY4742 deleted strain, using primers MSY1DFw and MSY1DRv (Supplementary Data, table e-1). Transformation of the former strain was performed, thus obtaining W303-1Bmsy1 /pFL38-MSY1. MSY1 fragment was subcloned from pFL38 to pFL39 4 . MSY1 was mutagenised by PCR overlap technique 7 with appropriate primers (Supplementary  Table e1 ) to obtain the allelic variants msy1 hL391C , msy1 L391Y , msy1 L411S and subsequently cloned into the pFL39 vector.
W303-1Bmsy1 /pFL38-MSY1 was transformed with pFL39-MSY1, pFL39-msy1 hL391C , pFL39-msy1 L391Y , pFL39-msy1 L411S or the empty vector pFL39. pFL38-MSY1 was lost through plasmidshuffling.
Yeast mitochondrial respiration
Respiration rate was measured at 30°C from yeast cell suspensions cultured for 18 hours at 28˚C in SC medium supplemented with 0.6% glucose until exhaustion using a Clark-type oxygen electrode (Oxygraph System Hansatech Instruments England) with 1 ml of air-saturated respiration buffer (0.1 M phthalate-KOH, pH 5.0), 0.5% glucose.
